June 22, 2021 -LMT’s Comprehensive Sales and Support Network to Meet Significant Demand for the MolecuLight i:X® in the Wound Care Community
TORONTO, CANADA and QUEENSLAND, AUSTRALIA– (June 22, 2021) MolecuLight Inc., the leader in point-of-care fluorescence imaging for detection of wounds containing elevated bacterial loads, announces it has signed… Read More
May 18, 2021 -Results of Clinical Integration Project of MolecuLight i:X® Point-of-Care Imaging Device Illustrate Improved Access, Effectiveness and Efficiency of Wound Care
TORONTO, Ontario – (May 18, 2021) MolecuLight Inc., the leader in point-of-care fluorescence imaging for detection of wounds containing elevated bacterial loads, is helping to improve wound care in
… Read MoreMay 6, 2021 -Patient Wounds Documented by MolecuLight i:X Device Now Integrated with EHR Systems Through Net Health’s Tissue Analytics Platform
Pittsburgh, PA and Toronto, ON – May 6, 2021 – MolecuLight, the leader in point-of-care fluorescence imaging for real-time detection of bacteria in wounds, announced today that the company has partnered with… Read More
May 4, 2021 -Contract Awarded for Products that Bring Improvement to the Health Care Industry
PITTSBURGH, PA – (May 4, 2021) MolecuLight Corp., the leader in point-of-care fluorescence imaging for detection of wounds containing elevated bacterial loads, announces its MolecuLight i:X® fluorescence wound imaging device has received an Innovative Technology contract from
… Read MoreApril 8, 2021 -Distributors’ Extensive Support and Technical Expertise will Meet Growing Global Demand for the MolecuLight i:X® Fluorescence Wound Imaging Device
Toronto, Canada – (April 8, 2021) MolecuLight Inc., the leader in point-of-care fluorescence imaging for detection of wounds containing elevated bacterial loads, announced that it has appointed 11 specialized… Read More
March 9, 2021 -Leading GPO Selects MolecuLight i:X Point-of-Care Device as a Key Tool for Informing its National Long-Term Care Membership on the Presence of Elevated Bacterial Burden in Patients’ Wounds
Valley Stream, NY and Toronto, CANADA – (March 9, 2021) MolecuLight Inc., the leader in fluorescence imaging for
… Read MoreMarch 2, 2021 -Study Reveals the Utility of Cyan Fluorescence to Reliably Predict Pseudomonas, a Bacterial Pathogen that Precludes Wound Healing and Often Evades Conventional Treatment Methods
Toronto, Canada – (March 2, 2021) MolecuLight Inc., the leader in point-of-care fluorescence imaging for point-of-care detection of wounds containing elevated bacterial
… Read MoreDecember 10, 2020 -MolecuLight i:X will Provide Essential Real-Time Information to Assist Wound Care Plus’s Advanced Wound Care Consultants in Providing the Highest Quality Wound Care
Toronto, Canada and Midwest, USA – (December 10, 2020) MolecuLight Inc., the leader in point-of-care fluorescence imaging for real-time detection of wounds containing bacteria, announced that Wound
… Read MoreNovember 25, 2020 -Study also Reveals that Routine Use of Fluorescence Imaging Along with Clinical Assessment Resulted in Significant Reductions in Antibiotic Usage and Antimicrobial Dressing Costs
Toronto, Canada and London, UK – (November 25, 2020) MolecuLight Inc., the leader in point-of-care fluorescence imaging for real-time detection of wounds containing bacteria, announced the
… Read More
MolecuLight is SOC ll®
Type l Accredited:
MolecuLight awarded
Premier’s Technology
Breakthrough Designation
MolecuLight i:X
is designated as a:
MolecuLight included
in ISWCAP Consensus
Guidelines:
MolecuLight is a proud
corporate member of:
©2024
The MolecuLight® i:X and MolecuLightDX™ Imaging Devices are approved by Health Canada for sale in Canada and has CE marking for sale in the European Union.
The MolecuLight™ i:X and DX Imaging Devices have received FDA clearance.